Enliven Therapeutics (ELVN) Accounts Payables (2019 - 2026)

Enliven Therapeutics has disclosed Accounts Payables across 8 years of filings, most recently posting $1.6 million for Q1 2026.

• Accounts Payables for Q1 2026 came in at $1.6 million, up 4.99% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.6 million (up 4.99% YoY), and the FY2025 annual result was $2.2 million, up 60.88% from the prior year.
• Accounts Payables came in at $1.6 million for Q1 2026 at Enliven Therapeutics, down from $2.2 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $5.9 million in Q1 2023 to a low of $532000.0 in Q4 2023.
• The 5-year median for Accounts Payables is $1.6 million (2025), against an average of $2.0 million.
• Peak annual rise in Accounts Payables reached 211.04% in 2023, while the deepest fall reached 84.53% in 2023.
• Enliven Therapeutics' Accounts Payables stood at $3.4 million in 2022, then sank by 84.53% to $532000.0 in 2023, then jumped by 152.26% to $1.3 million in 2024, then jumped by 60.88% to $2.2 million in 2025, then decreased by 24.04% to $1.6 million in 2026.
• The last three Accounts Payables figures came in at $1.6 million (Q1 2026), $2.2 million (Q4 2025), and $1.4 million (Q3 2025), per Business Quant data.